Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance

Abstract excerpt

Homologous recombination (HR) repair deficiency impairs the proper maintenance of genomic stability, thus rendering cancer cells vulnerable to loss or inhibition of DNA repair proteins, such as poly(ADP-ribose) polymerase-1 (PARP-1). Inhibitors of nuclear PARPs are effective therapeutics for a number of different types of cancers. Here we review key concepts and current progress on the therapeutic use of PARP...

Topics

Join the communities discussing this publication.

• DNA Repair Mechanisms
• Integrated Circuits and Semiconductor Failure Analysis
• PARP inhibition in cancer therapy